Dec 18 (Reuters) – Novo Nordisk said on Thursday it had filed a marketing application with the U.S. Food and Drug Administration for CagriSema, its once-weekly next-generation weight-loss drug.
The regulator is expected to review the application in 2026, Novo said.
The Danish drugmaker had positioned CagriSema as a more potent successor to its blockbuster drug, Wegovy, but lower-than-expected weight loss in two prior studies disappointed investors.
The drug combines cagrilintide, which mimics pancreatic hormone amylin, and semaglutide, the active ingredient in Novo’s blockbuster weight-loss drug Wegovy.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar; Editing by Anil D’Silva)
